Overall, according to the authors, the Perimount aortic valve (Edwards Lifesciences) provided the best long-term performance with a 10-year reoperation rate of 3%. The 10-year reoperation rates for the other valves included in the study were 3.5% for Mosaic/Hancock valves (Medtronic), 3.7% for Biocor/Epic valves (Abbott), 9.2% for Mitroflow/Crown valves (LivaNova) and 9.3% for the Soprano valve (LivaNova).
No 10-year data on the Trifecta (Abbott) valve was available, but its five-year reoperation rate of 2.2% put it in the middle of the pack.
Additionally, the authors found that the Perimount valve had the lowest all-cause mortality after 10 years (44%). The highest all-cause mortality rate after 10 years, meanwhile, was 70% observed in Mitroflow/Crown valves.
Additionally, looking specifically at hospitalizations for heart failure, the Perimount valve had the lowest rate after 10 years (14%) and the Mitroflow/Crown valves had the highest rate (25.9%).
“These results support the extensive use of the Perimount valve and suggest the need for increased clinical vigilance in patients who receive either a Soprano valve or a Mitroflow/Crown valve,” the authors wrote.
Related content on structural heart disease:
When infective endocarditis after TAVR is most likely to be fatal
How Modified Bioprosthetic Heart Valves Could Limit Calcification and Reduce the Need for TAVR
Recurrent MRI after TEER: follow-up data from nearly 700 MitraClip patients
Late-breaking clinical trials announced for ACC.22
1. Michael Persson, MD, Natalie Glaser, MD, PhD, Johan Nilsson, MD, PhD, et al. Comparison of long-term performance of bioprosthetic aortic valves in Sweden from 2003 to 2018. JAMA Netw Open. 2022;5(3):e220962.